Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it ...

After losing some value lately, a hammer chart pattern has been formed for Guardant Health (GH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange ...

Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The company’s revenue for the quarter was up 33.9% compared to the same quarter last year.

Guardant Health (NASDAQ:GH), a $5.49 billion market cap healthcare company, announced a significant step in its financial strategy, reaching an agreement to exchange a portion of its convertible notes ...

Fintel reports that on January 23, 2025, Barclays initiated coverage of Guardant Health (NasdaqGS:GH) with a Overweight recommendation. Analyst Price Forecast Suggests 12.31% Downside As of December ...

Guardant Health (GH) announced an agreement with the Abu Dhabi Public Health Center ADPHC to introduce a non-invasive blood-based screening ...